QIAGEN launches enhanced GeneGlobe Design & Analysis Hub, combining curated knowledge, content-based assays and analyses for life science research

Secure cloud-based platform now combines gene target exploration, custom assay configuration and data analysis with ability to conduct follow-up experiments

Hilden, Germany, and Germantown, Maryland, September 30, 2019  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its newly enhanced GeneGlobe Design & Analysis Hub, bringing next-level experiment planning, execution and follow-up to life science researchers.

GeneGlobe integrates QIAGEN’s deep, manually curated knowledge base on over 10,000 biological entities with the industry’s most comprehensive portfolio of tools for next-generation sequencing (NGS), polymerase chain reaction (PCR) and functional analysis. GeneGlobe users can quickly explore pathways and targets of interest in their scientific context and order the right tools. User-friendly custom product builders enable experiment design with full flexibility on target regions, configuration and format. Embedded analysis pipelines provide quick insights and support the planning of follow-up studies.

“Our new GeneGlobe hub empowers the journey of discovery with just one tool, streamlining the complete cycle of target exploration, product configuration, data analysis and follow-up experiments. GeneGlobe delivers fast, economical access to big data from rapidly expanding genomic knowledge with a first-class user experience. This unique tool will help scientists around the world accelerate life science research,” said Dr. Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area.

GeneGlobe supports every step of the research process with a trusted and comprehensive portfolio of NGS, PCR and functional analysis products, coupled to manually curated target and pathway data. The Ingenuity Target Explorer bioinformatics application links biological interpretation and references with GeneGlobe’s extensive library of wet-lab assay solutions, creating a new dimension of utility.

Key features and benefits available in the new GeneGlobe Design & Analysis Hub:

  • Enhanced navigation and user interface allows users to find the right product in just three steps, including gene- and pathway-specific solutions for qPCR, NGS, mRNA, lncRNA, miRNA gene expression analysis, microbial detection, RNAi, genotyping, epigenetics and functional analysis
  • Powerful algorithms link the relevant laboratory assays to biological targets, so users can explore and decide on products within each experiment’s goals and specific biological context
  • “My GeneGlobe” personal project space allows researchers to store biological target lists, custom designs and data analyses
  • Improved usability of custom product designers and builders allows creation of virtually any product for a specific research question

For more information about the new GeneGlobe Design & Analysis Hub, please visit https://geneglobe.qiagen.com/


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement 

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Did you like this article?